1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Demographics, endovascular treatments, and outcomes of treatment group
Demographics 
Gender 10 men, 4 women
Mean age (ys) ± SD 58 ± 14
Median baseline NIHSS (range) 17 (11–25)
Mean time (min) from stroke onset to endovascular therapy ±SD 389 ± 103
Thrombolytics 9 IV/IA, 3 IA, 1 IV, 1 none
Mean total IA dose ± SD Reteplase (n=8): 3 ± 1.2 mg (median 3 mg, range 1–4.9 mg)
Urokinase (n=2): 250,000–650,000 U
rtPA (n=2): 4–19 mg
Occlusion location 8 left, 6 right
Occlusion type 4 type II, 10 type III
Adjunctive therapy 2 simple mechanical, 5 angioplasty, 6 angioplasty/stenting
Immediate recanalization (TICI ≥ 2) 64%
Decrease in expected infarct volume 50%
ASPECT scores Mean 4 ± 2.9, median 3, range 0–8, 21% ≥ 8
Symptomatic hemorrhage 7%
Mortality 21%
Favorable outcome (discharge home or inpatient rehabilitation) 64%
Note.—NIHSS indicates National Institutes of Health Stroke Scale; IA, intraarterial; IV, intravenous; TICI, thrombolysis in cerebral infarction; ASPECT, Alberta Stroke Program Early CT.